Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.42 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915214 | 1.00 | NAAA (0.45) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL20915341 | 1.00 | NAAA (0.45) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL11240792 | 1.00 | NAAA (0.45) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL2785037 | 1.00 | NAAA (0.45) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL20936457 | 1.00 | NAAA (0.45) | NAAACES2HCAR2RAD52NPSR1 | |
| Ammonia Solution, Strong SCHEMBL11617704 | 0.98 | NAAA (0.44) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL254199 | 0.98 | CYP4F2 (0.43) | NAAACES2HCAR2RAD52NPSR1 | |
| SCHEMBL3291432 | 0.91 | ALDH1A1 (0.43) | HCAR2CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL2784638 | 0.89 | PPARG (0.51) | NPSR1PPARGPPARAPPARDTDP1 | |
| SCHEMBL2784643 | 0.89 | PPARG (0.51) | NPSR1PPARGPPARAPPARDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | NAAA 771/4885CES2 1954/4885HCAR2 220/4885 |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | NAAA 273/4885CES2 205/4885HCAR2 133/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | NAAA 771/4885CES2 1954/4885HCAR2 220/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | NAAA 771/4885CES2 1954/4885HCAR2 220/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | NAAA 1278/4885CES2 133/4885HCAR2 57/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | NAAA 273/4885CES2 205/4885HCAR2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.